Comparative Pharmacology
Head-to-head clinical analysis: INLYTA versus NINTEDANIB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INLYTA versus NINTEDANIB.
INLYTA vs NINTEDANIB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Axitinib is a tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3), which are involved in pathologic angiogenesis, tumor growth, and metastatic progression of cancer.
Nintedanib is a small molecule tyrosine kinase inhibitor that inhibits multiple receptor tyrosine kinases, including vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), platelet-derived growth factor receptors (PDGFR-α, PDGFR-β), and fibroblast growth factor receptors (FGFR-1, FGFR-2, FGFR-3). It also inhibits RET, FLT3, and Src family kinases. These receptors are involved in angiogenesis, proliferation, and fibrosis.
5 mg orally twice daily, approximately 12 hours apart, with or without food.
150 mg orally twice daily approximately 12 hours apart, taken with food.
None Documented
None Documented
Clinical Note
moderateNintedanib + Digoxin
"Nintedanib may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateNintedanib + Digitoxin
"Nintedanib may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateNintedanib + Deslanoside
"Nintedanib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateNintedanib + Acetyldigitoxin
"Nintedanib may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 13–17 hours in patients, supporting twice-daily dosing.
Terminal half-life: 9.5 hours (range 6-14 hours) in patients with IPF; supports twice-daily dosing.
Primarily hepatic metabolism via CYP3A4 and subsequent biliary-fecal elimination (approximately 61% of dose recovered in feces, 23% in urine as metabolites; <10% excreted unchanged in urine or feces).
Primarily fecal (85%) as unchanged drug; renal excretion accounts for <1%.
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor